Clinical Trials Browser

Phase 2 × Neoplasm, Residual × 90 days × Clear all

NCT03876769 2026-06-02

CASSIOPEIA

Phase 2 Active not recruiting

Burkitt Lymphoma, Neoplasm, Residual

NCT06500273 2026-06-02

ALPHA3

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse, Neoplasm, Residual

NCT07136077 2026-06-01

A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

Phase 2 Recruiting

Gastrointestinal

Colorectal Neoplasms, Neoplasm, Residual

NCT06993675 2026-05-13

ROTATE

Phase 2 Recruiting

Multiple Myeloma, Neoplasm, Residual

NCT07517705 2026-05-13

MRD-Adapted Low-Dose Radiation Therapy During Frontline Chemoimmunotherapy for Diffuse Large B-Cell Lymphoma

Phase 2 Not yet recruiting

Lymphoma, Large B-Cell, Diffuse, Neoplasm, Residual

NCT07572929 2026-05-07

PREeMPT

Phase 2 Not yet recruiting

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT04434040 2026-05-04

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

Phase 2 Recruiting

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT03863184 2026-04-28

Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL

Phase 2 Active not recruiting

37 enrolled 9 charts

Neoplasm, Residual, Lymphoma, Mantle-Cell

NCT07069595 2026-04-22

PREDICT-RD

Phase 2 Recruiting

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT04768426 2026-04-13

Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer

Phase 2 Recruiting

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT04841148 2026-04-09

PALAVY

Phase 2 Recruiting

Breast Neoplasms, Neoplasm, Residual

NCT07392970 2026-04-09

Motixafortide for MRD Sensitization in AML

Phase 2 Not yet recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT05735717 2026-04-06

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

Phase 2 Recruiting

CNSClassical hematologyLymphoidOther hematologic neoplasm

Chromosome 7, monosomy, Anemia, Refractory, with Excess of Blasts, Chromosome Aberrations, Influenza, Human, Neurofibromatosis 1, Leukemia, Myeloid, Acute, beta-Thalassemia, Neoplasm, Residual, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myelomonocytic, Juvenile

NCT03516279 2026-04-03

Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease

Phase 2 Active not recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Chronic-Phase, Neoplasm, Residual

NCT07507318 2026-04-02

DEL-MRD-CHID

Phase 2 Not yet recruiting

Lymphoma, Large B-Cell, Diffuse, Neoplasm, Residual

NCT05690984 2026-03-16

EMAT

Phase 2 Active not recruiting

Multiple Myeloma, Neoplasm, Residual